TSHA
NASDAQTaysha Gene Therapies Inc.
News · 26 weeks41+300%
2026-03-012026-08-23
Mix2490d
- SEC Filings8(33%)
- Other6(25%)
- Insider5(21%)
- Earnings3(13%)
- Offering2(8%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 10-Q filed by Taysha Gene Therapies Inc.10-Q - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- SECTaysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- PRTaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateCompleted dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through ≥12 months post-TSHA-102, with consistent responses across ages and disease severity Advanced TSHA-102 commercial readiness activities, including market access planning initiative
- PRTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement
- PRTaysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on
- PRTaysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett SyndromeCAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (NASDAQ:TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha’s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha’s primary commercial manufacturer followin
- INSIDERPresident and Head of R&D Nagendran Sukumar sold $1,248,000 worth of shares (200,000 units at $6.24) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 936,410 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 8-K filed by Taysha Gene Therapies Inc.8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- SECSEC Form 424B5 filed by Taysha Gene Therapies Inc.424B5 - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- PRTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingRecently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity Rett syndrome natural history data analysis shows a clear developmental plateau after 6 years of age, supporting a stable, well-defined population to evaluate TSHA-102 in the REVEAL pivotal trial New data support the developmental milestone assessment (DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies Preclinical data demonstrated superior MeCP2 expression of self-complementary AAV9 compared to single-stranded, supporting effective CNS delivery
- PRTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsDALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the secur
- SECSEC Form 424B5 filed by Taysha Gene Therapies Inc.424B5 - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- PRTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsDALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of $200.0 million shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its com
- SECTaysha Gene Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- PRTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett SyndromeCompleted dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated with no treatment-related SAEs or DLTs reported as of the June 2026 data cutoff across REVEAL Phase 1/2 and pivotal trials (N=29) 100% of REVEAL Part A patients (N=12, 6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102, with consistent responses across ages and disease severity Longer-term follow‑up showed a durable and deepening treatment effect ≥12 months post-TSHA-102, with functional gains accumulating over time across core disease domains
- PRTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company's common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, I
- INSIDERDirector Stalfort John A Iii was granted 21,335 shares, increasing direct ownership by 2% to 1,176,559 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- INSIDERDirector Sepp-Lorenzino Laura was granted 21,335 shares, increasing direct ownership by 20% to 127,178 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- INSIDERDirector Long Alison S was granted 21,335 shares, increasing direct ownership by 20% to 127,178 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- INSIDERDirector Donenberg Phillip B. was granted 21,335 shares, increasing direct ownership by 10% to 241,289 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- SECSEC Form 8-K filed by Taysha Gene Therapies Inc.8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
TSHA FAQ
7 questionsWhat does Taysha Gene Therapies Inc. do?
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to...Where does TSHA stock trade?
Taysha Gene Therapies Inc. (TSHA) is listed on NASDAQ.What sector and industry is TSHA in?
Taysha Gene Therapies Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Taysha Gene Therapies Inc. go public?
Taysha Gene Therapies Inc. (TSHA) completed its IPO in 2020.What are analysts saying about TSHA?
Taysha Gene Therapies Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1300.00 price target on 2025-10-21.What companies are similar to TSHA?
Notable peers in the same industry include ABEO (Abeona Therapeutics Inc.), SIOX (Sio Gene Therapies Inc.), PASG (Passage Bio Inc.). Compare TSHA side-by-side with any of them on Quantisnow.How can I track TSHA on Quantisnow?
Quantisnow aggregates Taysha Gene Therapies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TSHA to receive live email and push alerts on every new disclosure.